Eccogene Announces Completed First-in-human of ECC0509 in Phase 1a Clinical Trial in Australia
SHANGHAI,July 28, 2021/PRNewswire/ -- Eccogene, Inc., a clinical stage biopharmaceutical company focused on discovery and development of metabolic and immunologic therapeutics, announced the initiation of a Phase 1a clinical trial evaluating ECC0509, an oral inhibitor of semicarbazide-se